



PATENT
ATTORNEY DOCKET NO.: GENE1120-1

**AMENDMENT UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE – GROUP ART UNIT NO.: 1636**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Nolan and Filshie Art Unit: 1636
Application No.: 09/342,024 Examiner: G. Leffers, Jr.
Filed: June 28, 1999
Title: HIGH EFFICIENCY TRANSFECTION BASED ON LOW ELECTRIC
FIELD STRENGTH, LONG PULSE LENGTH

ATTN: BOX AF
Commissioner for Patents
Washington, D.C. 20231

**DECLARATION OF DIETMAR P. RABUSSAY
UNDER 37 C.F.R. §1.132**

Sir:

I, Dietmar P. Rabussay, do hereby declare and state that:

1. I presently hold the position of Vice President of Research and Development at Genetronics, Inc., having a place of business at 11199-A Sorrento Valley Road, San Diego, California 92121-1334.

2. Genetronics, Inc. is the Assignee of 100 percent interest in U. S. Patent No. 5,944,710 to Dev et al., issued August 31, 1999, entitled ELECTROPORATION-MEDIATED INTRAVASCULAR DELIVERY, as evidenced by the Assignment to Genetronics, Inc., recorded on September 3, 1996 in the United States Patent and Trademark Office on Reel 8112, Frame 0497.

PATENT
ATTORNEY DOCKET NO.: GENE1120-1

Applicants: Nolan and Filshie
Application No.: 09/342,024
Filed: June 28, 1999
Page 2

3. Genetronics, Inc. is the Assignee of 100 percent interest in U.S. Patent Application Serial No. 09/342,024, filed June 28, 1999, entitled HIGH EFFICIENCY TRANSFECTION BASED ON LOW ELECTRIC FIELD STRENGTH, LONG PULSE LENGTH, as evidenced by the Assignment recorded on February 8, 2000 in the United States Patent and Trademark Office on Reel 010536, Frame 0720.

4. Genetronics, Inc. was co-owner of the subject matter of U.S. Patent Application Serial No. 09/342,024, filed June 28, 1999 and U.S. Patent No. 5,944,710 at the time of the respective inventions.

5. I further declare that all statements made herein of knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine, or imprisonment, or both under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: February 27 2003

Rabussay

Dietmar P. Rabussay